Unique MicroRNA-profiles in EGFR-mutated Lung Adenocarcinomas

Overview

Journal Int J Cancer

Specialty Oncology

Date 2014 Mar 7

PMID 24599520

Citations 36

Authors

Maria Moksnes Bjaanaes

Ann Rita Halvorsen

Steinar Solberg

Lars Jorgensen

Tommaso A Dragani

Antonella Galvan

Francesca Colombo

Marco Anderlini

Ugo Pastorino

Elin Kure

Anne-Lise Borresen-Dale

Odd Terje Brustugun

Aslaug Helland

Affiliations

Soon will be listed here.

Abstract

The findings of mutations and the development of targeted therapies have improved lung cancer management. Still, the prognosis remains poor, and we need to know more about the genetic and epigenetic alterations in lung cancer. MicroRNAs are involved in crucial biological processes like carcinogenesis by regulating gene expression at the post-transcriptional level. In this project, we have studied the microRNA expression of lung adenocarcinomas and corresponding normal lung tissue and correlated the expression with clinical data and EGFR- and KRAS-mutational status. Agilent microarrays have been used, examining microRNA expression in 154 surgically resected lung adenocarcinomas and 20 corresponding normal lung tissue samples. Findings were confirmed by RT-qPCR in the same cohort and in an independent cohort of 103 lung cancer patients. EGFR and KRAS mutation analyses were also performed. 129 microRNAs were significantly differentially expressed in lung adenocarcinomas compared with normal lung tissue, and 17 microRNAs were differentially expressed between EGFR-mutated and EGFR wildtype tumors. We identified microRNAs associated with time to progression. We have identified several aberrantly expressed microRNAs that discriminate lung adenocarcinomas from normal lung tissue, and hence may be potential biomarkers for early detection. We have found microRNAs that are differentially expressed between EGFR-mutated and EGFR wildtype lung adenocarcinomas, suggesting that microRNAs can be used as molecular biomarkers in classification. We hypothesize that microRNA expression can be used as biomarkers for clinical course.

Citing Articles

Tumor-targeted miRNA nanomedicine for overcoming challenges in immunity and therapeutic resistance.

Parayath N, Gandham S, Amiji M Nanomedicine (Lond). 2022; 17(19):1355-1373.

PMID: 36255330 PMC: 9706370. DOI: 10.2217/nnm-2022-0130.

Contributions of Circulating microRNAs for Early Detection of Lung Cancer.

Vykoukal J, Fahrmann J, Patel N, Shimizu M, Ostrin E, Dennison J Cancers (Basel). 2022; 14(17).

PMID: 36077759 PMC: 9454665. DOI: 10.3390/cancers14174221.

Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands.

Hassanein S, Ibrahim S, Abdel-Mawgood A Int J Mol Sci. 2021; 22(22).

PMID: 34830377 PMC: 8621388. DOI: 10.3390/ijms222212496.

Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors.

Bjaanaes M, Nilsen G, Halvorsen A, Russnes H, Solberg S, Jorgensen L BMC Cancer. 2021; 21(1):1089.

PMID: 34625038 PMC: 8501630. DOI: 10.1186/s12885-021-08811-7.

miR‑200b upregulation promotes migration of BEAS‑2B cells following long‑term exposure to cigarette smoke by targeting ETS1.

Wang J, Yao R, Luo Q, Tan L, Jia B, Ouyang N Mol Med Rep. 2021; 24(2).

PMID: 34109431 PMC: 8201442. DOI: 10.3892/mmr.2021.12201.

References

Nakamoto M, Jin P, ODonnell W, Warren S . Physiological identification of human transcripts translationally regulated by a specific microRNA. Hum Mol Genet. 2005; 14(24):3813-21. DOI: 10.1093/hmg/ddi397. View

Vosa U, Vooder T, Kolde R, Fischer K, Valk K, Tonisson N . Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer. Genes Chromosomes Cancer. 2011; 50(10):812-22. DOI: 10.1002/gcc.20902. View

Li J, Xiao X, Zhang Y, Wang Y, Feng L, Wu Y . MicroRNA miR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells. Gynecol Oncol. 2010; 120(1):145-51. DOI: 10.1016/j.ygyno.2010.09.009. View

Iorio M, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P . MicroRNA signatures in human ovarian cancer. Cancer Res. 2007; 67(18):8699-707. DOI: 10.1158/0008-5472.CAN-07-1936. View

Sagerup C, Smastuen M, Johannesen T, Helland A, Brustugun O . Sex-specific trends in lung cancer incidence and survival: a population study of 40,118 cases. Thorax. 2011; 66(4):301-7. DOI: 10.1136/thx.2010.151621. View

Xu T, Liu X, Han L, Shen H, Liu L, Shu Y . Up-regulation of miR-9 expression as a poor prognostic biomarker in patients with non-small cell lung cancer. Clin Transl Oncol. 2013; 16(5):469-75. DOI: 10.1007/s12094-013-1106-1. View

Lewis B, Burge C, Bartel D . Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1):15-20. DOI: 10.1016/j.cell.2004.12.035. View

Markou A, Tsaroucha E, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou E . Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem. 2008; 54(10):1696-704. DOI: 10.1373/clinchem.2007.101741. View

Shen Y, Tang D, Yao R, Wang M, Wang Y, Yao Y . microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation. Med Oncol. 2013; 30(4):750. DOI: 10.1007/s12032-013-0750-1. View

10.

Cho W . MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2009; 42(8):1273-81. DOI: 10.1016/j.biocel.2009.12.014. View

11.

Malhas A, Saunders N, Vaux D . The nuclear envelope can control gene expression and cell cycle progression via miRNA regulation. Cell Cycle. 2010; 9(3):531-9. DOI: 10.4161/cc.9.3.10511. View

12.

Moriya Y, Nohata N, Kinoshita T, Mutallip M, Okamoto T, Yoshida S . Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. J Hum Genet. 2011; 57(1):38-45. DOI: 10.1038/jhg.2011.126. View

13.

Hamfjord J, Stangeland A, Skrede M, Tveit K, Ikdahl T, Kure E . Wobble-enhanced ARMS method for detection of KRAS and BRAF mutations. Diagn Mol Pathol. 2011; 20(3):158-65. DOI: 10.1097/PDM.0b013e31820b49e2. View

14.

Volinia S, Galasso M, Sana M, Wise T, Palatini J, Huebner K . Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A. 2012; 109(8):3024-9. PMC: 3286983. DOI: 10.1073/pnas.1200010109. View

15.

John B, Enright A, Aravin A, Tuschl T, Sander C, Marks D . Human MicroRNA targets. PLoS Biol. 2004; 2(11):e363. PMC: 521178. DOI: 10.1371/journal.pbio.0020363. View

16.

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M . Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9(3):189-98. DOI: 10.1016/j.ccr.2006.01.025. View

17.

Seike M, Goto A, Okano T, Bowman E, Schetter A, Horikawa I . MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A. 2009; 106(29):12085-90. PMC: 2715493. DOI: 10.1073/pnas.0905234106. View

18.

Vivanco I, Sawyers C . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501. DOI: 10.1038/nrc839. View

19.

L Bartels C, Tsongalis G . [MicroRNAs: novel biomarkers for human cancer]. Ann Biol Clin (Paris). 2010; 68(3):263-72. DOI: 10.1684/abc.2010.0429. View

20.

Dysvik B, Jonassen I . J-Express: exploring gene expression data using Java. Bioinformatics. 2001; 17(4):369-70. DOI: 10.1093/bioinformatics/17.4.369. View